Raymond James Believes Teva Pharmaceutical (TEVA) Still Has Room to Grow


Raymond James analyst Elliot Wilbur maintained a Buy rating on Teva Pharmaceutical (TEVA) today. The company’s shares closed last Tuesday at $12.55, close to its 52-week high of $13.76.

According to TipRanks.com, Wilbur is a 1-star analyst with an average return of -1.3% and a 45.8% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Amneal Pharmaceuticals, and Flexion Therapeutics.

Teva Pharmaceutical has an analyst consensus of Hold, with a price target consensus of $10.25.

See today’s analyst top recommended stocks >>

Teva Pharmaceutical’s market cap is currently $13.11B and has a P/E ratio of -3.20. The company has a Price to Book ratio of -0.64.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts